MX2007008137A - Triazoloftalazinas como inhibidores de pde2. - Google Patents

Triazoloftalazinas como inhibidores de pde2.

Info

Publication number
MX2007008137A
MX2007008137A MX2007008137A MX2007008137A MX2007008137A MX 2007008137 A MX2007008137 A MX 2007008137A MX 2007008137 A MX2007008137 A MX 2007008137A MX 2007008137 A MX2007008137 A MX 2007008137A MX 2007008137 A MX2007008137 A MX 2007008137A
Authority
MX
Mexico
Prior art keywords
triazolophthalazines
meanings
compounds
formula
given
Prior art date
Application number
MX2007008137A
Other languages
English (en)
Spanish (es)
Inventor
Beate Schmidt
Hans-Peter Kley
Dieter Flockerzi
Steffen Weinbrenner
Hermann Tenor
Raimund Kulzer
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of MX2007008137A publication Critical patent/MX2007008137A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
MX2007008137A 2005-01-05 2006-01-04 Triazoloftalazinas como inhibidores de pde2. MX2007008137A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05100045 2005-01-05
EP05100044 2005-01-05
PCT/EP2006/050041 WO2006072615A2 (en) 2005-01-05 2006-01-04 Triazolophthalazines as pde2-inhibitors

Publications (1)

Publication Number Publication Date
MX2007008137A true MX2007008137A (es) 2007-07-19

Family

ID=36604687

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008137A MX2007008137A (es) 2005-01-05 2006-01-04 Triazoloftalazinas como inhibidores de pde2.

Country Status (15)

Country Link
US (1) US8106047B2 (enExample)
EP (1) EP1836207B1 (enExample)
JP (1) JP5240899B2 (enExample)
KR (1) KR20070095986A (enExample)
CN (1) CN101103033B (enExample)
AU (1) AU2006204454B2 (enExample)
BR (1) BRPI0606379A2 (enExample)
CA (1) CA2592007C (enExample)
EA (1) EA012505B1 (enExample)
ES (1) ES2397080T3 (enExample)
IL (1) IL183919A (enExample)
MX (1) MX2007008137A (enExample)
NO (1) NO20073921L (enExample)
NZ (1) NZ555661A (enExample)
WO (1) WO2006072615A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005021894D1 (de) * 2004-09-02 2010-07-29 Nycomed Gmbh Triazolophthalazine
JP5130053B2 (ja) * 2005-01-05 2013-01-30 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
EA012505B1 (ru) 2005-01-05 2009-10-30 Никомед Гмбх Триазолофталазины в качестве ингибиторов pde-2
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
EP2718295A1 (en) * 2011-06-07 2014-04-16 Pfizer Inc Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
MX361539B (es) 2012-04-25 2018-12-10 Takeda Pharmaceuticals Co Compuesto heterociclico nitrogenado.
WO2013166276A1 (en) * 2012-05-02 2013-11-07 Southern Research Institute Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
WO2014010732A1 (ja) * 2012-07-13 2014-01-16 武田薬品工業株式会社 複素環化合物
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
WO2015002230A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 アミド化合物
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
CN103694244B (zh) * 2014-01-09 2016-03-30 郑州大学 3,6位取代-1,2,4-三氮唑并[3,4-a]酞嗪类化合物及其制备和用途
HRP20212035T1 (hr) 2014-04-23 2022-04-01 Dart Neuroscience Llc Pripravci koji sadrže supstituirane [1,2,4]triazolo[1,5-a]pirimidin-7-il spojeve kao inhibitore pde2
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
MX371158B (es) 2014-12-06 2020-01-20 Intra Cellular Therapies Inc Compuestos inhibidores de pde2.
AU2015357498B2 (en) 2014-12-06 2019-09-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2016145614A1 (en) * 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
WO2016179059A1 (en) 2015-05-05 2016-11-10 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
JP2021504466A (ja) 2017-11-23 2021-02-15 オスロ ウニヴェルシティ ホスピタル ホーエフ 頻脈の治療

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI81350C (fi) * 1982-01-18 1990-10-10 Lepetit Spa Analogfoerfarande foer framstaellning av nya, farmakologiskt aktiva 6-substituerade s-triatsolo/3,4-a/ ftalazinderivat.
IT1194310B (it) * 1983-07-12 1988-09-14 Lepetit Spa Derivati triazolo (3,4-a) ftalazinici 3,6-disostituiti
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
IL127911A0 (en) 1996-07-25 1999-11-30 Merck Sharp & Dohme Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
DE69807074T2 (de) 1997-05-08 2003-04-03 Merck Sharp & Dohme Ltd., Hoddesdon Substituierte 1,2,4-triazolo[3,4,-a]phthalazin-derivate als gaba-alpha 5-liganden
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
GB9715977D0 (en) * 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
AU2841801A (en) 1999-12-24 2001-07-09 Bayer Aktiengesellschaft Triazolotriazinones and the use thereof
GB0028583D0 (en) * 2000-11-23 2001-01-10 Merck Sharp & Dohme Therapeutic compounds
US6958334B2 (en) * 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
WO2004022062A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
DE602005021894D1 (de) 2004-09-02 2010-07-29 Nycomed Gmbh Triazolophthalazine
EA012505B1 (ru) 2005-01-05 2009-10-30 Никомед Гмбх Триазолофталазины в качестве ингибиторов pde-2
JP5130053B2 (ja) 2005-01-05 2013-01-30 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン

Also Published As

Publication number Publication date
EA012505B1 (ru) 2009-10-30
JP2008526717A (ja) 2008-07-24
NZ555661A (en) 2010-11-26
JP5240899B2 (ja) 2013-07-17
WO2006072615A3 (en) 2007-01-04
US8106047B2 (en) 2012-01-31
IL183919A0 (en) 2007-10-31
CA2592007C (en) 2013-12-10
AU2006204454B2 (en) 2011-11-10
NO20073921L (no) 2007-07-26
CA2592007A1 (en) 2006-07-13
EA200701396A1 (ru) 2007-12-28
EP1836207B1 (en) 2012-10-10
WO2006072615A2 (en) 2006-07-13
US20080312225A1 (en) 2008-12-18
EP1836207A2 (en) 2007-09-26
IL183919A (en) 2011-06-30
CN101103033B (zh) 2010-08-04
ES2397080T3 (es) 2013-03-04
AU2006204454A1 (en) 2006-07-13
BRPI0606379A2 (pt) 2009-06-23
KR20070095986A (ko) 2007-10-01
CN101103033A (zh) 2008-01-09
HK1116776A1 (en) 2009-01-02

Similar Documents

Publication Publication Date Title
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
ZA200701137B (en) Triazolophthalazines
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
TW200640924A (en) VEGF-R2 inhibitors and methods
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
MX2009008798A (es) Derivados de iminipiridina y sus usos como microbicidas.
MY149957A (en) Heterocyclic inhibitors of mek and methods of use thereof
SI1761520T1 (sl) Inhibitorji kinaze
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
EA200701707A1 (ru) Пиразолопиримидины
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
MX2008001538A (es) Aril piridinas y metodos para su uso.
UA85505C2 (en) Kinase inhibitors
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
MY154498A (en) Pyrazolone derivatives as pde4 inhibitors
TW200700358A (en) Organic compounds
EA200901179A1 (ru) Замещённые тетрагидрохинолины
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
MX2008001541A (es) Metodos para la preparacion de inhibidores de polimerasa del vhc.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status